New use for an old drug: Metformin and atrial fibrillation

Manlio Vinciguerra; Ivan Olier; Sandra Ortega-Martorell; Gregory Y H Lip

doi:10.1016/j.xcrm.2022.100875

New use for an old drug: Metformin and atrial fibrillation

Cell Rep Med. 2022 Dec 20;3(12):100875. doi: 10.1016/j.xcrm.2022.100875.

Authors

Manlio Vinciguerra¹, Ivan Olier², Sandra Ortega-Martorell², Gregory Y H Lip³

Affiliations

¹ Liverpool Centre for Cardiovascular Science (LCCS) at University of Liverpool, Liverpool Heart and Chest Hospital, Liverpool John Moores University, Liverpool, UK; Faculty of Health, Liverpool John Moores University, Liverpool, UK.
² Liverpool Centre for Cardiovascular Science (LCCS) at University of Liverpool, Liverpool Heart and Chest Hospital, Liverpool John Moores University, Liverpool, UK; School of Computer Science and Mathematics, Liverpool John Moores University, Liverpool, UK.
³ Liverpool Centre for Cardiovascular Science (LCCS) at University of Liverpool, Liverpool Heart and Chest Hospital, Liverpool John Moores University, Liverpool, UK; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Electronic address: gregory.lip@liverpool.ac.uk.

Abstract

Lal and colleagues¹ reported an integrative approach-combining transcriptomics, iPSCs, and epidemiological evidence-to identify and repurpose metformin, a main first-line medication for the treatment of type 2 diabetes, as an effective risk reducer for atrial fibrillation.

Publication types

Comment

MeSH terms

Atrial Fibrillation* / drug therapy
Atrial Fibrillation* / epidemiology
Diabetes Mellitus, Type 2* / drug therapy
Humans
Metformin* / therapeutic use

Substances

Metformin